Delving into the Latest Updates on Jiangsu Huayang Pharmaceutical Co. Ltd. with Synapse

Overview

Tags

Neoplasms

Digestive System Disorders

Nervous System Diseases

Oncolytic virus

ASO

Recombinant polypeptide

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	18
Nervous System Diseases	9
Endocrinology and Metabolic Disease	1

Top 5 Drug Type	Count

Oncolytic virus	15
ASO	11
Recombinant polypeptide	1

Top 5 Target	Count

pendrin(solute carrier family 26 member 4)	1
APP(Beta amyloid A4 protein)	1
DMD exon 53(Dystrophin exon 53)	1
COX-2 x PGE2	1
Cep290(Centrosomal protein of 290 kDa)	1

[Translation] A single-center, randomized, open-label, two-dose, fasting and fed, single-dose, 2-sequence, 4-period, repeated crossover bioequivalence study of edoxaban tosylate tablets developed by Jiangsu Huayang Pharmaceutical Co., Ltd. and Risenan® marketed by Daiichi Sankyo Europe GmbH in healthy subjects

以江苏华阳制药有限公司生产的甲苯磺酸艾多沙班片（30 mg）为受试制剂，以Daiichi Sankyo Europe GmbH上市的里先安®为参比制剂，考察两制剂在空腹及餐后状态下单次给药的药代动力学参数及相对生物利用度，评价两制剂是否具有生物等效性；同时评价两种制剂在健康人体中的安全性和耐受性。

[Translation]

Edoxaban tosylate tablets (30 mg) produced by Jiangsu Huayang Pharmaceutical Co., Ltd. were used as the test preparation, and Risenan® marketed by Daiichi Sankyo Europe GmbH was used as the reference preparation. The pharmacokinetic parameters and relative bioavailability of the two preparations after single administration in the fasting and postprandial states were investigated to evaluate whether the two preparations were bioequivalent. At the same time, the safety and tolerability of the two preparations in healthy humans were evaluated.

Start Date16 Jul 2024

Sponsor / Collaborator

Jiangsu Huayang Pharmaceutical Co. Ltd.

CTR20230917 / CompletedNot Applicable

江苏华阳制药有限公司研制的卡格列净片与Janssen Cilag S.p.A.生产的卡格列净片在中国健康受试者中进行的单中心、随机、开放、两制剂、单次给药、两周期、双交叉、空腹及餐后状态下的生物等效性研究

[Translation] A single-center, randomized, open-label, two-dose, single-dose, two-period, double-crossover, fasting and fed bioequivalence study of canagliflozin tablets developed by Jiangsu Huayang Pharmaceutical Co., Ltd. and canagliflozin tablets produced by Janssen Cilag S.p.A. in healthy Chinese subjects

以江苏华阳制药有限公司生产的卡格列净片（规格：300mg）为受试制剂，以Janssen Cilag S.p.A.生产的卡格列净片（INVOKANA®，规格：300mg）为参比制剂，考察两制剂在空腹及餐后状态下单次给药的药代动力学参数及相对生物利用度，评价两制剂是否具有生物等效性。同时评价两种制剂在健康人体中的安全性和耐受性。

[Translation]

Canagliflozin tablets (specification: 300 mg) produced by Jiangsu Huayang Pharmaceutical Co., Ltd. were used as the test preparation, and canagliflozin tablets (INVOKANA®, specification: 300 mg) produced by Janssen Cilag S.p.A. were used as the reference preparation. The pharmacokinetic parameters and relative bioavailability of the two preparations after single administration in the fasting and postprandial states were investigated to evaluate whether the two preparations were bioequivalent. At the same time, the safety and tolerability of the two preparations in healthy humans were evaluated.

Start Date04 Jul 2024

Sponsor / Collaborator

Jiangsu Huayang Pharmaceutical Co. Ltd.

CTR20242212 / CompletedNot Applicable

江苏华阳制药有限公司研制的富马酸伏诺拉生片与原研参比制剂在中国健康受试者中进行的单中心、随机、开放、两制剂、空腹和餐后、单次给药、两周期、双交叉设计的生物等效性研究

[Translation] A single-center, randomized, open-label, two-dose, fasting and postprandial, single-dose, two-period, double-crossover bioequivalence study of vonoprazan fumarate tablets developed by Jiangsu Huayang Pharmaceutical Co., Ltd. and the original reference preparation in healthy Chinese subjects

以江苏华阳制药有限公司研制的富马酸伏诺拉生片（规格：20 mg）为受试制剂，生产厂家为Takeda Pharmaceutical Company Limited的富马酸伏诺拉生片（商品名：沃克®/Vocinti®，规格：20 mg）为参比制剂，考察两制剂在空腹及餐后状态下单次给药的药代动力学参数及相对生物利用度，评价两制剂是否具有生物等效性。同时评价两种制剂在健康人体中的安全性和耐受性。

[Translation]

The vonoprazan fumarate tablets (specification: 20 mg) developed by Jiangsu Huayang Pharmaceutical Co., Ltd. were used as the test preparation, and the vonoprazan fumarate tablets (trade name: Walker®/Vocinti®, specification: 20 mg) produced by Takeda Pharmaceutical Company Limited were used as the reference preparation. The pharmacokinetic parameters and relative bioavailability of the two preparations after single administration in the fasting and postprandial states were investigated to evaluate whether the two preparations were bioequivalent. At the same time, the safety and tolerability of the two preparations in healthy humans were evaluated.

Start Date25 Jun 2024

Sponsor / Collaborator

Jiangsu Huayang Pharmaceutical Co. Ltd.

100 Clinical Results associated with Jiangsu Huayang Pharmaceutical Co. Ltd.

Login to view more data

0 Patents (Medical) associated with Jiangsu Huayang Pharmaceutical Co. Ltd.

Login to view more data

1

Literatures (Medical) associated with Jiangsu Huayang Pharmaceutical Co. Ltd.

Zhejiang Huagong

Synthesis of isomeric impurities of edoxaban toluene sulfonate

Author: Xu, Jin ; Wang, Zi-yue

Edoxaban toluene sulfonate (EDXB) enantiomers and epimers can affect the quality of API and related preparationsThe preparation and liquid phase separation control of EDXB isomers can effectively control the content of isomeric impurities in EDXB drugs and improve the quality of drugs.The synthetic process of EDXB isomeric impurities was studied with 3-cyclohexene-1-carboxylic acid and phenylethylamine as starting materials.The isomeric impurities and EDXB drugs were separated and purity confirmed by high performance liquid chromatog.Structures of the three isomeric impurities were characterized by NMR.In this paper, high-purity EDXB enantiomers (1R, 2S, 4R), EDXB epimers (1R, 2R, 4S) and EDXB epimers (1s, 2S, 4R) were prepared, which could solve the current market shortage of EDXB isomers.

100 Deals associated with Jiangsu Huayang Pharmaceutical Co. Ltd.

Login to view more data

100 Translational Medicine associated with Jiangsu Huayang Pharmaceutical Co. Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 24 Dec 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Discovery

13

Preclinical

Phase 1 Clinical

1

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

NV-A01	Advanced Malignant Solid Neoplasm More	Phase 1
FYNM-003 ( DMD exon 45 )	Muscular Dystrophy, Duchenne More	Preclinical
FYNM-004 ( Nav1.7 )	Pain More	Preclinical
Huntington Disease(Suzhou Antian Shengshi)	Huntington Disease More	Preclinical
FYCR-001 ( PD-1 )	Liver Cancer More	Preclinical